6,245 Shares in R1 RCM Inc. (NASDAQ:RCM) Purchased by Values First Advisors Inc.

Values First Advisors Inc. bought a new stake in R1 RCM Inc. (NASDAQ:RCM) during the third quarter, Holdings Channel.com reports. The institutional investor bought 6,245 shares of the healthcare provider’s stock, valued at approximately $88,000.

Several other hedge funds also recently bought and sold shares of RCM. Advisors Asset Management Inc. acquired a new position in shares of R1 RCM in the first quarter worth $27,000. GAMMA Investing LLC increased its holdings in R1 RCM by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,597 shares of the healthcare provider’s stock worth $37,000 after purchasing an additional 759 shares during the period. Allspring Global Investments Holdings LLC raised its position in R1 RCM by 589.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,122 shares of the healthcare provider’s stock valued at $44,000 after purchasing an additional 2,669 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in shares of R1 RCM in the 2nd quarter valued at about $86,000. Finally, Creative Planning purchased a new position in shares of R1 RCM in the 3rd quarter valued at about $142,000. Hedge funds and other institutional investors own 61.10% of the company’s stock.

R1 RCM Price Performance

RCM stock opened at $14.25 on Friday. The stock has a 50-day moving average price of $14.15 and a two-hundred day moving average price of $13.18. The company has a market cap of $6.00 billion, a PE ratio of -178.13 and a beta of 0.85. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.77. R1 RCM Inc. has a 12-month low of $8.87 and a 12-month high of $15.12.

R1 RCM (NASDAQ:RCM) last posted its earnings results on Wednesday, August 7th. The healthcare provider reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The firm had revenue of $627.90 million during the quarter, compared to the consensus estimate of $633.10 million. R1 RCM had a negative net margin of 1.68% and a negative return on equity of 1.44%. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. As a group, research analysts predict that R1 RCM Inc. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on RCM. Stephens downgraded shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Morgan Stanley cut R1 RCM from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 8th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of R1 RCM in a research report on Monday, July 22nd. Truist Financial cut their target price on R1 RCM from $16.00 to $14.30 and set a “hold” rating on the stock in a research report on Thursday, August 8th. Finally, Leerink Partnrs lowered shares of R1 RCM from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Thirteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $15.41.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.